Jul22546 EU Business News - Q4 2025 r. Katleen Verleysen is a visionary leader maintaining an impressive position at the very cutting-edge of advancement. Recognised as an instrumental player within the life sciences sector, she has dedicated more than two decades to advancing and enhancing its operations – leveraging her broad expertise to lead the charge. She is uniquely prepared to steer this mission, having achieved a significant volume of academic and professional success since first entering the field. Katleen’s journey began with the achievement of a B.Sc. and PhD in Analytical Chemistry from Ghent University, followed by a postdoctoral fellowship at Duke University, North Carolina, within the Department of Pharmacology and Cancer Biology. More recently, she has completed certification in Artificial Intelligence: Implications for Business Strategy from MIT Sloan School of Management. Across her educational experiences, Katleen received a high calibre of rigorous scientific training that contributed towards reshaping her mindset. She developed an unwavering commitment to evidencebased thinking, analytical precision, and a continuous drive to explore and learn. These are principles that have long served Katleen, guiding her through every stage of her career in the life sciences sector. Over the last 20 years, Katleen has been instrumental in founding, funding, and successfully exiting multiple biotech and medtech companies across both the US and Europe, holding various CEO, Senior Management positions, and Board roles across the sector. This has included serving as CEO at Pronota, CellSeeQ, and DNameIt; and holding Board of Director positions at ImmunExpress, PharmaFluidics, and the Center for Medical Innovation. Every stage of Katleen’s professional journey has been a continuous learning experience – from producing early stage proof-of-concepts to delivering scalable products. These moments have taught Katleen how to effectively navigate complexity, build performing teams centred around a shared vision, and translate cutting-edge science into tangible value for patients and healthcare systems alike. Today, CEO Katleen stands at the helm of miDiagnostics, steering the team with an expert hand. miDiagnostics was founded in 2015, as a spin-out of the global nanoelectronics leader imec with a large scale strategic collaboration with Johns Hopkins University, a premier medical research facilitation. Now, the company is on a mission to redefine the future of diagnostics and quality control tests for biomanufacturing. Connecting advanced engineering with critical medical needs, miDiagnostics supports a wide range of partners in pharmaceutical services, healthcare systems, and diagnostics. Its focus, however, lies in cell and gene therapy manufacturing – where its impact will be most tangible. After a decade, miDiagnostics now stands as a renowned Best Health Screening Solutions CEO 2025 (Belgium): Katleen Verleysen Healthcare professionals are increasingly demanding quick, high quality testing technology for rapid and reliable results. Enter miDiagnostics, a healthcare technology company redefining the future of diagnostics and quality control tests for biomanufacturing. Steering this forward-thinking firm is Dr. Katleen Verleysen, its CEO and a key figure in the life sciences sector. We caught up with Katleen below for more information, in the wake of her recent recognition in the European CEO of the Year Awards 2025. D Contact: Dr. Katleen Verleysen Company: miDiagnostics Web Address: www.midiagnostics.com Jun25084
RkJQdWJsaXNoZXIy MTUyMDQwMA==